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Blood pressure (BP) measured only in the clinic substantially
misclassifies hypertension in patients with chronic kidney
disease (CKD). The role of out-of-clinic recordings of BP in
predicting end-stage renal disease (ESRD) and death in
patients with CKD is unknown. A prospective cohort study
was conducted in 217 Veterans with CKD. BP was measured
at home and in the clinic by ‘routine’ and standardized
methods. Patients were followed over a median of 3.5 years
to assess the end points of total mortality, ESRD or the
composite outcome of ESRD or death. Home BP was
147.0721.4/78.3711.6 mmHg and clinic BPs were
155.2725.6/84.7714.2 mmHg by standardized method and
144.5724.2/75.4714.7 mmHg by the ‘routine’ method. The
composite renal end point occurred in 75 patients (34.5%),
death in 52 patients (24.0%), and ESRD in 36/178 patients
(20.2%). One standard deviation (s.d.) increase in systolic BP
increased the risk of renal end point by 1.27 (95% confidence
interval (CI) 1.01–1.60) for routine clinic measurement, by
1.69 (95% CI 1.32–2.17) for standardized clinic measurement
and by 1.84 (95% CI 1.46–2.32) for home BP recording. One
s.d. increase in home systolic BP increased the risk of ESRD by
1.74 (95% CI 1.04–2.93) when adjusted for standardized clinic
systolic BP, proteinuria, estimated glomerular filtration rate,
and other risk factors. In patients with CKD, BPs obtained at
home are a stronger predictor of ESRD or death compared to
BPs obtained in the clinic. Systolic home BP is an
independent predictor for ESRD.
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Chronic kidney disease (CKD) affects 11% of the US adult
population1 and among those with CKD, hypertension is
seen in at least 70%.2 Blood pressure (BP) control to o130/
80 mmHg is currently the goal of antihypertensive therapy in
patients with CKD.3 To achieve these goals without over-
treating or undertreating hypertension, increasingly accurate
assessment of BP is required. Nevertheless, clinic-based BP
recording even when performed in a standard manner, is
insufficient in classifying hypertension.4 We have recently
shown that approximately 26% of patients who have a
normal BP in the clinic have high BP at home – masked
hypertension.5 Conversely, 29% of patients who are hyper-
tensive in the clinic have well-controlled BP at home – white-
coat hypertension. Misclassification of BP can result in
misdirected treatment of hypertension and can influence the
prediction of morbidity and mortality.
Home BP monitoring allows measurement of BP in the
out-of-office setting and current guidelines recommend its
use to better evaluate and target antihypertensive therapy.6
Large randomized controlled trials in essential hypertension
show excellent correlation between achieved home BP and
outcomes.7 In population-based studies, home BP monitor-
ing better predicts cardiovascular morbidity and mortality
compared to clinic-based recordings.8 Home BP monitoring
can substantially reduce the number of people who are
classified as masked hypertension or white-coat hyperten-
sion. The test performance characteristics of home BP
monitoring as measured by the area under the receiver
operating-characteristic curve is better than clinic-based BP
recordings.5
Although home BP monitoring has excellent test perfor-
mance characteristics in patients with CKD, its role in
predicting ‘hard’ renal end points such as end-stage renal
disease (ESRD) and death is unknown. We hypothesized that
in patients with CKD, home BP monitoring will improve the
prediction of renal and total mortality when compared to
clinic BPs.
RESULTS
A total of 424 patients were screened for the study of whom
277 (65%) qualified. Of these, 217 (78%) had adequate
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recordings of home and clinic BPs. Seven patients had no
routine clinic BP recordings, 25 had no or inadequate home
BP recordings, 27 had stage 2 CKD but no microalbuminuria,
and one had no laboratory measurements; they were excluded.
The baseline characteristics of these 217 subjects are
shown in Table 1. The older age and predominance of men is
consistent with the Veteran population.
Median follow-up was 3.5 years (inter-quartile range
2.9–3.9 years). During this follow-up period, 52 (24%)
patients died and 75 (34.5%) had the combined end point of
ESRD or death. Thirty-nine patients died before reaching
ESRD; of the 178 remaining patients, 36 reached ESRD
(20.2%). The crude mortality rate was 74.2/1000 patient-
years, ESRD rate was 62.6/1000 patient-years and the
combined end-point rate was 116.7/1000 patient-years.
Table 2 shows the results of the ESRD, death or the
combined end point. Diastolic BPs, regardless of the
technique, were not useful in predicting the composite
end point. High home diastolic BPs were predictive of
ESRD and low routine clinic diastolic BPs were predictive
of death.
Systolic BP regardless of the technique was predictive of
the ESRD, death or the combined end point, except that
routine systolic BP was not predictive of death. In unadjusted
analyses, each standard deviation increase in systolic BP
increased the risk of the combined end point by 27% for
routine clinic BP, by 69% for standardized clinic BP, and by
84% for home BP. The magnitude of risk for ESRD was
greatest for home systolic BP (210%), less for standardized
systolic BP (175%), and least for routine clinic systolic BP
(70%). Diastolic BP elevation by one standard deviation
increased the risk for ESRD by 46% only when BP was
measured at home or by 42% when BP was measured in a
standardized manner in the clinic. Total mortality was
increased by 39% by one standard deviation increase in
standardized clinic BP and by 50% by home systolic BP. An
inverse relationship between diastolic BP and total mortality
was seen. The risk of death was decreased by 28% by one
standard deviation increase in routine diastolic BP but not by
standardized diastolic BP or home diastolic BP.
Figure 1 shows that the relationship of ESRD to clinic BP
measurement is modified by home systolic BP. Figure 1a and
b show the relationship of routine clinic BP and ESRD
outcomes. Among patients with good routine BP (Figure 1a),
0/19 participants with home systolic BP o130 mmHg had
ESRD. In contrast, 6/27 (22%) participants with good
routine clinic systolic BP, but poorly controlled home systolic
BP, had ESRD. Among patients with poor routine systolic BP
control (Figure 1b), 0/16 with home systolic BPo130 mmHg
reached ESRD, whereas 30/116 (26%) patients with poor
home systolic BP control reached ESRD.
Among patients with well-controlled standardized clinic
systolic BP measurement, 0/12 with poor home systolic BP,
and 0/17 with good home systolic BP had ESRD (Figure 1c).
In those patients who had poor systolic BP control by
standardized clinic measurement, 0/18 with good home
systolic BP but 36/131 (28%) with poor home systolic BP
reached ESRD (Figure 1d).
For each one standard deviation increase in home systolic
BP, the risk of composite end point was increased by 84%,
ESRD by 210%, and total mortality by 50% (Table 3).
Adjustments for eight risk factors for ESRD – age, race,
diabetes mellitus, log protein/creatinine ratio, estimated
glomerular filtration rate (GFR), serum albumin, hemoglo-
bin, and angiotensin-converting enzyme inhibitor, or angio-
tensin receptor blocker use – reduced the risk of composite
end points but did not remove the statistical significance.
Similarly, adjustments for neither routine clinic systolic BP
nor standardized clinic systolic BP reduced the statistical
significance of the results. When home systolic BP was
adjusted for risk factors noted above and standardized clinic
Table 1 | Clinical characteristics of the study population
Clinical characteristic N=217
Age (years) 67.4 (10.9)
Men 209 (96.3%)
Race
White 172 (79.3%)
Black 44 (20.3%)
Other 1 (0.5%)
Weight (kg) 94 (24.3)
Height (inches) 69 (3.4)
Body mass index (kg/m2) 30.5 (6.8)
Alcohol user 42 (19.4%)
Smoking
Current 44 (20.3%)
Former 131 (60.4%)
Never 42 (19.4%)
Diabetes mellitus 91 (41.9%)
History of gout or active disease 42 (19.4%)
Coronary artery disease 83 (38.2%)
Cerebrovascular disease 29 (13.4%)
Peripheral vascular disease 42 (19.4%)
Etiology of CKD
Diabetes mellitus 80 (36.9%)
Hypertension 115 (53.0%)
Glomerulonephritis 12 (5.6%)
Obstruction 6 (2.8%)
Other 4 (1.8%)
Number receiving antihypertensive
drugs
199 (91.7%)
Angiotensin-converting enzyme
inhibitors
104 (47.9%)
Angiotension receptor blockers 41 (18.9%)
Serum cholesterol (mg/dl) 182 (37.0)
Serum albumin (g/dl) 3.8 (0.4)
Hemoglobin (g/dl) 13.2 (1.8)
Urine protein/creatinine (median;
interquartile range)
0.143 (0.073–0.787)
Blood urea nitrogen (mg/dl) 31.5 (17.5)
Serum creatinine (mg/dl) 2.0 (0.97)
Estimated GFR (ml/min/1.73 m2) 44.8 (21.7)
Routine clinic BP (mmHg) 144.5 (24.2)/75.4 (14.7)
Standardized clinic BP (mmHg) 155.2 (25.6)/84.7 (14.2)
Home BP (mmHg) 147.0 (21.4)/78.3 (11.6)
Values are means (standard deviation) or numbers (percent).
BP: blood pressure; CKD: chronic kidney disease; GFR: glomerular filtration rate.
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systolic BP, one standard deviation increase in home systolic
BP still yielded 74% increase in ESRD risk.
Finally, home systolic BPs were divided into three
categories, o130, 130–o160, and 160 mmHg or more,
reflecting nationally recommended levels of control, and
two degrees of poor control.9 We found that none of the 35
patients in the well-controlled category had ESRD, 14/98
(14%) patients in 130–o160 mmHg had ESRD, and 22/45
Table 2 | Hazard ratios associated with the technique of BP monitoring
Systolic BP Diastolic BP
Standard deviation of
systolic BP (mmHg)
Hazard
ratio
95% confidence
interval
Standard deviation of
diastolic BP (mmHg)
Hazard
ratio
95% confidence
interval
End-stage renal disease or death
Routine clinic 24.2 1.27 1.01–1.60 14.7 0.92 0.73–1.16
Standardized clinic 25.6 1.69 1.32–2.17 14.2 0.91 0.80–1.28
Home 21.4 1.84 1.46–2.32 11.6 1.06 0.85–1.34
End-stage renal disease
Routine clinic 24.2 1.7 1.24–2.34 14.7 1.1 0.80–1.52
Standardized clinic 25.6 2.75 1.87–4.04 14.2 1.42 1.03–1.97
Home 21.4 3.10 2.17–4.41 11.6 1.46 1.07–1.99
Death
Routine clinic 24.2 1.09 0.83–1.43 14.7 0.72 0.55–0.95
Standardized clinic 25.6 1.39 1.04–1.85 14.2 0.75 0.56–1.01
Home 21.4 1.5 1.13–1.98 11.6 0.77 0.57–1.04
BP: blood pressure.
Hazard ratios are reported for one standard deviation change in systolic and diastolic BP.
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Figure 1 | Cumulative risk of ESRD according to category of systolic clinic BP. (a, b) Patients separated by routine systolic clinic BP.
(a) Represents those with well-controlled hypertension (o130 mmHg systolic by routine clinic systolic BP) and (b) represents poor control
by routine systolic clinic BP (4130 mmHg systolic). The upper line in (a) shows that those with BP poorly controlled BP at home but normal
in the clinic – masked hypertension – have a higher rate of ESRD. The plus signs at the bottom of (a) show censored observations. (b) Patients
with well-controlled home BP but poorly controlled clinic hypertension – white-coat hypertension – have no ESRD (plus signs at the bottom).
Thus, those with poorly controlled home systolic BP have worse outcomes (upper line). (c, d) Patients separated by standardized systolic clinic
BP. (c) None of the patients who had well-controlled standardized clinic BP had ESRD (panel c). Patients with well-controlled home BP
but poorly controlled standardized clinic BP – white-coat hypertension – did not have any ESRD events (plus signs at the bottom of panel d).
Those with poorly controlled home BP had ESRD events (d, upper line). Thus, poor control of home systolic BP appears to be a good marker
for ESRD events.
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(49%) in the 160 mmHg or more category had ESRD. The
linear trend between severity of hypertension and occurrence
of ESRD was significant by the log-rank test (Po0.0001).
DISCUSSION
The results of our prospective cohort study demonstrate that,
after adjustment for clinic BP, home BP provided additional
prognostic information concerning ESRD and the composite
end point of ESRD and death. After adjustment for risk
factors for ESRD, including clinic BP, home BP provided
additional prognostic information concerning ESRD.
Although a similar study that links ESRD outcome to
home BP monitoring is not available for comparison, the
results of our study are consistent with previously published
cohort studies examining the influence of home BP with
clinic BPs. For example, the prognostic importance of home
BP monitoring has been evaluated in a large rural commu-
nity-based study in Japan.8 The investigators reported that
among 1789 subjects aged 40 years or more, home BP
measurement had a stronger predictive power for mortality
than clinic BP. In a second study, 4939 treated elderly
hypertensive patients with mean age of 70 years had clinic
and home BP recorded and were followed for 3.2 years.10
Whereas each 10/5 mmHg increase in systolic and diastolic
BP measured at home increased the cardiovascular mortality
by 17.2/11.7%, no similar increase was associated with clinic
BP recordings.
We have previously shown that home BP recordings rather
than clinic BPs correlate better with the diagnosis of
hypertension made by ambulatory BP monitoring.5 The
stronger correlation may be due to several reasons. First,
timing of the administration of antihypertensive drugs can be
variable, and multiple BP measurements over the course of
the day, as made with home BP monitoring, can therefore
average out the troughs and peaks in BP swings, which clinic
BP recordings are unable to do.11 Second, clinic BPs are
influenced by the white-coat effect – elevated BP only in the
office setting – which is less pronounced with home BPs.12
Also, masked hypertension – elevated BP at home but normal
in the clinic – is reduced with home BP monitoring.5 Finally,
clinic BPs are often taken with less frequency than home BPs,
and more frequent BP measurements at home may average
out the variability in BPs.11 Repeated clinic BP recordings
obtained by nurses or home BP monitoring by the patients
are therefore recommended.13
Our results show that masked hypertension – elevated
routine clinic BP and normal home BP14 – was associated
with ESRD in 6 of 27 (22%) patients. These findings are
similar to those reported in other populations with hard end
points. For example, in the elderly treated hypertensives,
those with masked hypertension had a twofold increase in
cardiovascular mortality compared to well-controlled hyper-
tension.10 Also, in patients with masked hypertension, the
prevalence of left-ventricular hypertrophy measured by
echocardiogram was as high as that seen with patients with
uncontrolled hypertension.15 Furthermore, white-coat hyper-
tension in 0/19 patients by routine BP monitoring, and 0/17
patients with standardized clinic BP monitoring, was also
not associated with ESRD. This misclassification as a result of
clinic BP monitoring may contribute to poorer prediction of
renal outcomes with clinic BP monitoring.
Our study was largely limited to older men with
concomitant illnesses and a single center. We also excluded
patients with morbid obesity and atrial fibrillation owing to
difficulties with accurate BP assessment in this population.
Whether the same results would hold in women and younger
people and over several centers needs further study. The
home BP monitor we used was not equipped with a memory
device or printer; so there was no way to confirm the
authenticity of the patient reports.16 Misreporting of home
BP recordings may reduce the strength of the relationship
between BP and renal end points. If a substantial number of
subjects misreported the results, the relationship between
home hypertension and renal end points may further
strengthen if memory-equipped devices are used. There are
also no data available that show superiority of outcomes
when home BPs, rather than clinic BPs, are used to guide
therapy.
Routine measurement of BP in patients with CKD is
imprecise in predicting ESRD. At the very least, standardized
Table 3 | Hazard ratios for renal end points associated with home systolic BP
ESRD or death ESRD Total mortality
BP technique
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Unadjusted 1.84 1.46–2.32 3.1 2.17–4.41 1.5 1.13–1.98
Adjusteda 1.13 0.82–1.54 1.8 1.12–2.86 0.95 0.64–1.41
Adjusted for routine clinic systolic BP 1.84 1.43–2.38 2.94 2.02–4.29 1.57 1.15–2.13
Adjusted for routine clinic systolic BP and
other factorsa
1.18 0.85–1.63 1.79 1.11–2.90 1.05 0.70–1.59
Adjusted for standardized clinic systolic BP 1.61 1.21–2.15 2.37 1.56–3.60 1.39 0.97–1.98
Adjusted for standardized clinic systolic BP
and other factorsa
1.27 0.88–1.82 1.74 1.04–2.93 1.27 0.80–2.01
BP: blood pressure.
Hazard ratios are reported for one standard deviation change in BP.
aModel was adjusted for age, race, diabetes mellitus, log protein/creatinine ratio, estimated Modification of Diet in Renal Disease glomerular filtration rate, serum albumin,
hemoglobin, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use.
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BP measurements should be obtained in clinics treating
patients with CKD.
A post hoc analysis of a clinical trial in patients with
diabetic nephropathy did not find BP to be an independent
predictor of ESRD or death.17 In contrast, our study found
systolic home BP recording to be an independent predictor of
renal events, suggesting that home BP recording may need to
be incorporated in future trials of patients with CKD; this
may potentially alter the results of trials using office-based BP
measurements in patients with CKD.18
The high rate of morbidity and mortality associated with
CKD is predicted to increase with the epidemic of diabetes
mellitus and an aging population.19 The high rates for ESRD
and death leave little time to intervene.20 The superior ability
to predict these events with the simple technique of home BP
monitoring provides an attractive tool to healthcare provi-
ders, which involves patients in the management of
hypertension for better lowering of BP – the single most
important measure to lower risk of ESRD. At this time, home
BP monitoring can complement, but it would be premature
to discontinue clinic BP monitoring in patients with CKD.
MATERIALS AND METHODS
Consecutive patients were recruited from the Renal and a General
Medicine Clinic at the Indianapolis Veterans Affairs Hospital
between November 2000 and June 2002 if they were X18 years of
age with an estimated GFR o60 ml/min/1.73 m2 by the abbreviated
four-component, Modification of Diet in Renal Disease formula or
GFRo90 ml/min/1.73 m2, and urine albumin/urine creatinine ratio
of430 mg/g.21 Patients were excluded for body mass index440 kg/m2
and in case of acute renal failure, receiving renal replacement therapy,
atrial fibrillation, or change in their antihypertensive regimens
within 2 weeks of study enrollment.
The Institutional Review Board of Indiana University and the
Research and Development Committee of the Richard L Roudebush
Veterans Affairs Medical Center approved this study, and all patients
gave their written, informed consent.
Clinic BPs
Standardized clinic BPs were obtained by one nurse trained in BP
measurement.6 Briefly, patients were seated for at least 5 min prior
to measurements and refrained from smoking or caffeine ingestion
for at least 30 min. The patient’s arm was kept at heart level during
the measurement, and using an appropriate sized cuff, three
measurements, via the Omron 412C semiautomatic BP monitor
(Omron Healthcare, Vernon Hills, IL, USA), were obtained in both
arms. At least 30 s elapsed between BP measurements, and were
performed only in the non-access arm if a dialysis access was
present. For each individual patient, the average BP from each arm
was calculated. The higher of the two averages was defined as the
patient’s standardized BP. The arm with the higher BP was used to
determine the home BP.
Routine clinic BPs were those obtained by the clinic nurses using
an automated device (DINAMAP 1846SX, Critikon, Tampa, FL,
USA). No protocol was defined to measure routine BPs. Standar-
dized clinic BPs were averaged over two visits: one was an afternoon
visit concurrent to the routine BP visit and a second was typically in
the morning.
Home BPs
After instruction in use by the research nurse, the patients recorded
their home BP via the same Omron 412C BP monitor that was used
to collect their standardized BP. The patients recorded their home
BPs in the morning, afternoon, and evening during 1 week and
recorded their BP into diaries. At the end of the week, both the
monitors and diaries were returned to the investigators. Because the
first day’s recordings of home BP may be inaccurate,22 the first day’s
results were discarded in calculating the patients’ home BP. For each
individual patient, the average of the entire home BP recordings,
except the first day’s values, was defined as the patient’s home BP.
Patients with o9 home BP were excluded from final analysis.
Outcomes
Renal outcomes were defined a priori and included a composite end
point of ESRD or death, whichever occurred first. ESRD and total
mortality were also analyzed as individual outcomes. The diagnosis
of ESRD was confirmed by confirming the date of first dialysis from
the patients’ medical record or the ESRD medical evidence report
form. Patients were censored on the date that they had the last clinic
visit.
Analysis
Cox proportional hazards regression was used to determine the
significance and strength of association of factors associated with
renal outcomes. The proportionality assumption was tested by
testing the significance of the time covariate interaction term.
Hazard ratios and 95% confidence intervals were calculated from the
proportional hazards model regression coefficients and their
standard errors for one standard deviation change in each BP.
Because all BPs were obtained in the same population, the hazard
ratios were not adjusted for the comparisons. The independent
effect of systolic home BP was tested by including the clinic systolic
BPs in the model. To further test the robustness of this finding, we
adjusted the hazard ratios for other confounders of ESRD, which
were ascertained from studies performed in similar population and
included age, race (Black vs non-Black), diabetes mellitus, log urine
protein/creatinine ratio, estimated GFR, serum albumin and
hemoglobin, and the use of angiotensin-converting enzyme inhibi-
tors or angiotensin receptor blockers.17 Kaplan–Meier survival
analyses were performed after stratification by routine clinic systolic
BP or standardized clinic systolic BP. Home systolic BP was tested as
a factor within each stratum by pairwise comparison using the log-
rank test. Home systolic BP of o130 mmHg was defined as well-
controlled BP.11 Significance was set at for a two-sided P-value of
o0.05. All analyses were performed by SPSS for Windows version
13.0 (SPSS Inc., Chicago, IL, USA).
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